# A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis

> **NCT01465529** · PHASE1,PHASE2 · COMPLETED · sponsor: **AlgiPharma AS** · enrollment: 26 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** OligoG CF-5/20
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT01465529
- **Lead sponsor:** AlgiPharma AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-10
- **Final completion:** 2013-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2015-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465529, "A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01465529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*